Hims & Hers: GLP-1 Partnership Could Unlock Value [Seeking Alpha]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Seeking Alpha
HIMS is expanding its offerings, including testosterone and potential at-home cancer screening, and is in renewed talks with Novo Nordisk for oral Wegovy distribution. Management guides for robust 4Q25 and full-year 2025 revenue and EBITDA, with international expansion and new partnerships fueling long-term growth. Despite near-term headwinds and a premium valuation, I remain bullish on HIMS, viewing the current dip as a buying opportunity ahead of potential catalysts. Maskot Bildbyrå/DigitalVision via Getty Images Thesis Hims & Hers Health, Inc. ( HIMS ) reported 3Q25 a GAAP EPS of $0.06, missing estimates by $0.04. Elsewhere, revenue of $598.98 million beat expectations by $19.13 million, which marked a 49% increase over the same period last year. For 4Q25, the company expects This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health (NYSE:HIMS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.MarketBeat
- Hims & Hers Continues Major International Expansion With Official Entry Into Canada [Yahoo! Finance]Yahoo! Finance
- A New Market, A New Catalyst: Assessing Hims & Hers' Canadian Opportunity [Seeking Alpha]Seeking Alpha
- Humana And Mark Cuban's Cost Plus Drugs Working On Partnership To Lower Prices [Forbes]Forbes
- Hims & Hers Health, Inc. (HIMS): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 12/2/25 - Form 4
- 12/2/25 - Form 4
- 11/25/25 - Form 4
- HIMS's page on the SEC website